Prelude Therapeutics, Inc. ((PRLD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prelude Therapeutics, Inc. is conducting a Phase 1 study titled ‘A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with specific advanced or metastatic solid tumors. This research is significant as it targets SMARCA4 mutations, which could lead to new therapeutic options for these challenging cancer types.
The intervention being tested is PRT7732, an experimental oral drug designed to degrade SMARCA2. It is administered as a capsule once daily, with dose adjustments guided by the Bayesian Logistic Regression Model (BLRM) until the recommended dose for expansion (RDE) is determined.
The study is interventional with a sequential intervention model and no masking, focusing on treatment as its primary purpose. This open-label, multi-center trial will enroll approximately 104 participants to assess the drug’s effects.
The study began on November 4, 2024, with its primary completion and estimated overall completion dates yet to be determined. The latest update was submitted on July 10, 2025, indicating ongoing recruitment and progress.
The market implications of this study are promising for Prelude Therapeutics, as positive results could enhance their stock performance and attract investor interest. The focus on SMARCA4 mutations positions Prelude in a competitive landscape, potentially setting them apart from other oncology-focused biotech firms.
The study is currently recruiting, with further details available on the ClinicalTrials portal.